A lipid/DNA adjuvant-inactivated influenza virus vaccine protects rhesus macaques from uncontrolled virus replication afer heterosubtypic influenza a virus challenge

Timothy D. Carroll, Sinthujan Jegaskanda, Shannon R. Matzinger, Linda Fritts, Michael B. McChesney, Stephen J. Kent, Jeffery Fairman, Christopher J. Miller

Research output: Contribution to journalArticleResearchpeer-review

8 Citations (Scopus)


Background. Influenza A virus (IAV) vaccines ofler little protection from mismatched viruses with antigenically distant hemagglutinin (HA) glycoproteins. We sought to determine if a cationic lipid/DNA complex (CLDC) adjuvant could induce heterosubtypic protection if added to a whole inactivated IAV vaccine (WIV). Methods. Adult rhesus macaques (RMs) were vaccinated and at 2 weeks boosted with either an H1N1-WIV or an H3N2-WIV, with and without CLDC adjuvant. Four weeks postboost, animals were challenged with an H1N1 IAV matched to the H1N1-WIV vaccine. Results. Afer challenge, viral RNA (vRNA) levels in the trachea of control RMs and RMs vaccinated with the unadjuvanted H1 or H3 WIV vaccines were similar. However, vRNA levels in the trachea of both the H1-WIV/CLDC-and the H3-WIV/CLDC-vaccinated RMs (P < 0.01 and P < 0.05, respectively) were signifcantly lower than in unvaccinated control RMs. Heterosubtypic protection in H3-WIV/CLDC RMs was associated with signifcantly higher levels of nucleoprotein (NP) and matrix-1-specifc immunoglobulin G antibodies (P < 0.05) and NP-specifc nonneutralizing antibody-dependent natural killer cell activation (P < 0.01) compared with unprotected H3-WIV RMs. Conclusions. Addition of the CLDC adjuvant to a simple WIV elicited immunity to conserved virus structural proteins in RMs that correlate with protection from uncontrolled virus replication afer heterosubtypic influenza virus challenge.

Original languageEnglish
Pages (from-to)856-867
Number of pages12
JournalThe Journal of Infectious Diseases
Issue number6
Publication statusPublished - 1 Jan 2018


  • Cross-reactive
  • NK cell activation
  • Non-neutralizing antibodies

Cite this